VFA
RIGL icon

Virtus Fund Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History

Virtus Fund Advisers’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$383K Buy
+9,873
New +$376K ﹤0.01% 370
2014
Q3 		– Sell
-747
Closed -$27K – 1768
2014
Q2 		$27K Buy
+747
New +$25.4K ﹤0.01% 2265

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Virtus Fund Advisers's RIGL Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Rigel Pharmaceuticals (RIGL) in Q4 2017: 9,873 shares worth $383K. The stake represents ﹤0.01% of the portfolio and ranks #370 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in RIGL as recently as Q2 2014.

Virtus Fund Advisers first reported a position in RIGL in Q2 2014 and has held it in 2 quarters since. 121 funds tracked by Wall St. Rank hold RIGL as of Q4 2017.

  • Virtus Fund Advisers held 9,873 shares of Rigel Pharmaceuticals worth $383K as of Q4 2017.
  • Rigel Pharmaceuticals was a new Virtus Fund Advisers position in Q4 2017.
  • Rigel Pharmaceuticals made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #370 holding.
  • Virtus Fund Advisers first reported a position in Rigel Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • 121 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.